Bure Equity AB (0N7D)
London Exchange · UK · prices in SEK · close of 19 Oct 2026
Key indicators
| Last close | SEK 293.00 |
|---|---|
| 52-week range | 191.10 – 327.60 |
| Return, 1 month / 3 months | −6.3% / +10.0% |
| Return, 1 year / 3 years | +8.7% / +38.8% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 39 |
| Volatility (1 year) | 32.1% |
| Worst drawdown (1 year) | -33.8% |
| Average daily value traded | 6.08M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Bure Equity is a Swedish investment company based in Stockholm that invests in other businesses, both unlisted and publicly traded. It takes active ownership positions in its portfolio companies and works closely with their management teams. Its investments span sectors such as healthcare, technology and industry, and its customers are essentially the companies it backs and the investors who put money into the firm. Bure Equity aims to build value over time through long-term involvement in the businesses it owns.
The shares are listed on the London Exchange in UK under the code 0N7D, and the price on this page is in Swedish kronor (SEK). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Bure Equity AB (0N7D) trades on the London Exchange in UK. It last closed at SEK 293.00 on 19 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 791 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 8.7% and over the last three months it rose 10.0%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 79 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 12.9% | ||
| From 52-week high | -10.5% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 10.0% | ||
| 6-month return | 10.7% | ||
| 12-month return, skipping the last month | 15.9% | ||
| Stability (higher is calmer) | 49 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 32.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -33.8% | ||
| Liquidity | 69 · Fair | Moderate trading activity. | |
| Average daily value traded | 6.08M SEK | ||
| Zero-volume days | 3.3% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −6.7% |
|---|---|
| 1 month | −6.3% |
| 3 months | +10.0% |
| 6 months | +10.7% |
| 1 year | +8.7% |
| 3 years | +38.8% |
| 5 years | – |
Signals
| 50-day / 200-day average | 304.31 / 259.58 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 18.83 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 9 May 2025 | SEK 2.7500 |
| 8 May 2024 | SEK 2.5000 |
| 4 May 2023 | SEK 2.2500 |
| 4 May 2022 | SEK 2.2500 |
| 7 May 2021 | SEK 2.0000 |
| 12 Jun 2020 | SEK 1.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.